Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2026-05-24 @ 2:15 PM
Study NCT ID:
NCT01968551
Status:
COMPLETED
Last Update Posted:
2018-11-16
First Post:
2013-09-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
Sponsor:
Gilead Sciences
Organization: